Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study examined molecular predictors of ritlecitinib efficacy in treating alopecia areata, highlighting the role of JAK3-dependent inflammation and follicular integrity as important factors in understanding disease mechanisms and potential therapeutic effectiveness.

This research discusses the parallel clinical development of ritlecitinib, an oral Janus kinase 3/tyrosine kinase inhibitor, for treating conditions such as alopecia areata, vitiligo, ulcerative colitis, Crohn's disease, and rheumatoid arthritis. Results are not reported in the abstract.

In this case report, researchers observed that a 35-year-old male with alopecia universalis achieved full regrowth of scalp, eyebrow, and facial hair with oral upadacitinib treatment after previous therapies failed to provide lasting relief.

This study used machine learning to identify molecular predictors of drug response in alopecia areata, suggesting a tool for predicting treatment efficacy based on gene signatures.

This study reports promising preliminary trends in the safety and efficacy of a botanical drug candidate for pediatric alopecia areata, but conclusive results are not yet available.

This study identified common and unexpected adverse events associated with ritlecitinib in real-world use, providing insights into its safety profile for treating severe alopecia areata.

This case study reports on a 13-year-old male with alopecia totalis who experienced successful hair regrowth after being treated with dupilumab, an interleukin-4 and IL-13 antagonist, suggesting its potential utility in managing alopecia areata in pediatric patients with comorbid atopic dermatitis.

This case study reports that a pediatric patient with recalcitrant alopecia areata was treated using a 308 nm excimer lamp and topical tofacitinib 2% gel.

This meta-analysis found that deuruxolitinib significantly improved hair regrowth and patient satisfaction in those with moderate to severe alopecia areata compared to placebo, though it was associated with manageable side effects such as elevated creatinine kinase levels, headaches, and acne, especially at higher doses.

CTP-543 is generally safe for treating alopecia areata.

This review discusses the potential of cold atmospheric plasma as a selective antitumor therapy for breast cancer but reports no clinical results, emphasizing its promise and the challenges to its use in precision oncology.

In this study, 37.5% of patients with nodal or metastatic cutaneous melanoma treated with immune checkpoint inhibitors developed skin adverse events, primarily low-grade rashes, vitiligo, and other dermatological symptoms, occurring mainly after 10 weeks of treatment.

This study reports a case where a biologic medication used for atopic dermatitis unexpectedly also treated concurrent alopecia areata.

This study identified mefloquine as a potent inducer of lethal ER stress that effectively eliminated vemurafenib-resistant and sensitive melanoma cells, suggesting its potential for repurposing as a melanoma treatment.

This study reviewed therapies for alopecia areata and suggests that Janus kinase inhibitors, such as baricitinib and upadacitinib, show promise in treating both alopecia areata and associated immune-mediated inflammatory diseases.

IMG-007 helps regrow hair and reduce scalp inflammation in severe alopecia areata.

This article presents a planned trial comparing radiotherapy and imiquimod for lentigo maligna treatment, noting a lack of direct evidence supporting current therapies, and aims to inform future treatment guidelines.

This systematic review and meta-analysis reported that deuruxolitinib is effective for hair regrowth and improving patient-reported outcomes in individuals with moderate to severe alopecia areata, but observed manageable treatment-emergent adverse events such as elevated creatinine kinase levels and headaches, particularly with higher doses.

This study reports a case where a patient with rheumatoid arthritis and alopecia areata saw significant improvement in both conditions after switching to daily upadacitinib treatment, specifically achieving complete hair regrowth within six months.

In this study, adult hereditary angioedema patients treated with lanadelumab at a Spanish hospital had a 94.1% reduction in angioedema episodes and needed 61% less on-demand medication, showing improved quality of life and minimal adverse effects.

In the phase 3 CAPItello-291 trial, capivasertib combined with fulvestrant significantly increased progression-free survival in patients with advanced breast cancer with specific genetic alterations, but the authors highlight that managing side effects like diarrhea, rash, and hyperglycemia is crucial for optimizing treatment adherence and outcomes.

This case report describes the first use of photobiomodulation therapy with a continuous wave red laser (660 nm) as monotherapy for alopecia areata, resulting in significant hair regrowth within 7 days, though further research is needed for conclusive evidence.

JAK inhibitors, like baricitinib and ritlecitinib, show promise in treating alopecia areata effectively and safely.

This article reviews treatment options for cutaneous T-cell lymphoma, including skin-directed therapies and aggressive treatments for advanced cases, but reports no new clinical results.

This article reports on a case where treatment-resistant giant unilateral Bowen’s disease of the scalp responded to radiotherapy, but provides no further clinical details or results.

This study observed that dupilumab may promote hair regrowth in alopecia areata patients, achieving significant results in a majority of cases without reported adverse events.

In this study, nearly one-third of patients with severe alopecia areata treated with ritlecitinib achieved complete scalp hair regrowth at least once over three years, and most maintained regrowth or stayed at low hair loss levels subsequently.

In this study, aumolertinib improved general health status, functional status, and key symptoms for patients with advanced NSCLC, with an objective response rate of 65.2% and disease control rate of 91.3%, suggesting efficacy and quality of life benefits in first-line treatment.